Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
AbbVie Inc. (NYSE: ABBV) has declared a quarterly cash dividend of $1.30 per share, payable on November 15, 2021, to stockholders of record by October 15, 2021. Since its inception in 2013, AbbVie has increased its dividend by 225% and is recognized as a member of the S&P Dividend Aristocrats Index, highlighting its commitment to consistent annual dividend increases over at least 25 consecutive years.
AbbVie (NYSE: ABBV) will showcase over 20 abstracts from its neuroscience portfolio at the MDS Virtual Congress 2021, scheduled for September 17-22. This includes long-term data on DUODOPA® for advanced Parkinson's disease and BOTOX® for spasticity and cervical dystonia. The research aims to address unmet needs in movement disorders, enhancing standards of care. The data will be accessible as virtual e-posters starting September 10, with a focus on real-world effectiveness and comparative studies related to patient outcomes.
AbbVie will participate in the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15, 2021, at 9:15 a.m. Central time. Key executives including Richard A. Gonzalez and Michael Severino will be presenting.
A live audio webcast will be available on AbbVie's Investor Relations website, with an archived version accessible later that day. AbbVie focuses on developing innovative medicines in areas such as immunology, oncology, and neuroscience, emphasizing impactful health solutions.
Genmab (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced the publication of results from the phase 1/2 EPCORE™ NHL-1 clinical trial in The Lancet. The trial evaluated the investigational therapy epcoritamab for B-cell non-Hodgkin’s lymphoma (B-NHL). Findings indicate a maximum tolerated dose of 48mg, with an overall response rate (ORR) of 88% and a complete response (CR) of 38% in patients treated with the RP2D. The results were presented at multiple medical congresses, highlighting the drug's potential in hematologic malignancies.
AbbVie and Genmab announced the publication of results from the dose escalation part of the Phase 1/2 EPCORE NHL-1 trial for epcoritamab, an investigational therapy targeting relapsed/refractory B-cell non-Hodgkin's lymphoma. The trial identified a recommended Phase 2 dose of 48mg with an overall response rate of 88% and a complete response rate of 38% in patients with DLBCL. Epcoritamab demonstrated a favorable safety profile, with common adverse events being primarily grade 1-2. The results underline significant interest in new treatment options for patients with hematologic malignancies.
AbbVie (NYSE: ABBV) announced the presentation of data from its migraine portfolio at the International Headache Congress 2021 from September 8-12. The company will share 23 abstracts, including clinical findings on atogepant, an investigational CGRP receptor antagonist for preventive migraine treatment. Key studies include a 40-week evaluation of atogepant's safety and efficacy, and real-world data on ubrogepant for acute migraine treatment. AbbVie aims to further advance its commitment to migraine research and improve patient outcomes.
On August 24, 2021, the European Commission approved RINVOQ (upadacitinib), a selective JAK inhibitor, for treating moderate to severe atopic dermatitis in patients aged 12 and older. The recommended doses are 15 mg or 30 mg daily for adults and 15 mg daily for adolescents. This approval follows robust Phase 3 clinical trials involving over 2,500 participants, which demonstrated a significant reduction in eczema symptoms. RINVOQ is already approved in several countries and is under review in the U.S. The treatment option aims to improve the quality of life for affected individuals.
AbbVie announced that the New England Journal of Medicine published results from the Phase 3 ADVANCE trial of atogepant for preventing migraines in adults with episodic migraine. The study showed all dose groups (10 mg, 30 mg, 60 mg) significantly reduced mean monthly migraine days compared to placebo, with reductions of 3.7, 3.9, and 4.2 days, respectively. Atogepant is under FDA review and aims to be the first oral treatment for episodic migraine prevention. The study included 910 patients and demonstrated significant efficacy across multiple endpoints.
AbbVie announced the launch of SKYRIZI® (risankizumab-rzaa) in the U.S. as a 150 mg single-dose injection for adults with moderate to severe plaque psoriasis. This new formulation reduces the administration frequency from two 75 mg injections to one 150 mg injection every 12 weeks after two starter doses. The FDA approved this dosage change based on clinical trials showing it offers the same efficacy and safety as the previous method. This innovation aims to enhance patient experience, reducing the number of injections required annually.
AbbVie announced the publication of 24-week results from the Phase 3b Heads Up study in JAMA Dermatology, showcasing the efficacy of RINVOQ (upadacitinib) over DUPIXENT (dupilumab) in treating moderate to severe atopic dermatitis in adults. At week 16, 71% of RINVOQ patients achieved at least a 75% improvement in eczema severity versus 61% for DUPIXENT. RINVOQ also resulted in faster reductions in itch and skin clearance. Despite a consistent safety profile, serious adverse events were noted, including one treatment-related death. The study will influence clinical treatment strategies for atopic dermatitis.